Back to News

Categories: News | Published On: June 3, 2024 | Written by webadmin@biolojic.com |

Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.

Back to News
More News
  • Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
    Read More
  • Biolojic Design Appoints Neal Curran as Chief Business Officer
    Read More
BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com